Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

In vitro and in vivo studies of galactose-modified liver-targeting liposomes.

Guo B, Cheng Y, Li N, Li X, Jin M, Li T, Li J.

J Drug Target. 2012 Nov 19. [Epub ahead of print]

PMID:
23163746
2.

Preparation and characterization of galactose-modified liposomes by a nonaqueous enzymatic reaction.

Guo BH, Cheng Y, Lin LP, Lin DH, Wu W.

J Liposome Res. 2011 Sep;21(3):255-60. doi: 10.3109/08982104.2011.573795. Epub 2011 May 6.

PMID:
21545336
3.

Distribution of liposomal bifendate in liver following intravenous injection in mice.

Zhipeng C, Jiabi Z, Hongxuan C, Yan-yu X, Jun C, Bao-chang C.

J Drug Target. 2010 Sep;18(8):627-36. doi: 10.3109/10611861003639788.

PMID:
20166805
4.

HPLC assay and pharmacokinetics and tissue distribution study of glycyrrhetinic acid liposomes modified with galactosylated lipid.

Guo BH, Cheng Y, Wu W, Lin LP, Lin DH.

J Liposome Res. 2012 Jun;22(2):120-7. doi: 10.3109/08982104.2011.627515. Epub 2012 Feb 7.

PMID:
22313057
5.

In vivo studies on the oridonin-loaded nanostructured lipid carriers.

Zheng D, Dai W, Zhang D, Duan C, Jia L, Liu Y, Zhang Q.

Drug Deliv. 2012 Aug;19(6):286-91. doi: 10.3109/10717544.2012.704096. Epub 2012 Aug 28.

PMID:
22928767
6.

Galactosylated chitosan nanoparticles for hepatocyte-targeted delivery of oridonin.

Zheng D, Duan C, Zhang D, Jia L, Liu G, Liu Y, Wang F, Li C, Guo H, Zhang Q.

Int J Pharm. 2012 Oct 15;436(1-2):379-86. doi: 10.1016/j.ijpharm.2012.06.039. Epub 2012 Jun 23.

PMID:
22732673
7.

In vitro and in vivo evaluation of oridonin-loaded long circulating nanostructured lipid carriers.

Jia L, Shen J, Zhang D, Duan C, Liu G, Zheng D, Tian X, Liu Y, Zhang Q.

Int J Biol Macromol. 2012 Apr 1;50(3):523-9. doi: 10.1016/j.ijbiomac.2012.01.024. Epub 2012 Jan 24.

PMID:
22301003
8.

In vitro and in vivo evaluation of mPEG-PLA modified liposomes loaded glycyrrhetinic acid.

Lu Y, Li J, Wang G.

Int J Pharm. 2008 May 22;356(1-2):274-81. doi: 10.1016/j.ijpharm.2007.12.047. Epub 2008 Jan 12.

PMID:
18304766
9.

Distribution of liposomal breviscapine in brain following intravenous injection in rats.

Lv W, Guo J, Li J, Huang L, Ping Q.

Int J Pharm. 2005 Dec 8;306(1-2):99-106. Epub 2005 Nov 8.

PMID:
16280216
10.

Preparation of itraconazole-loaded liposomes coated by carboxymethyl chitosan and its pharmacokinetics and tissue distribution.

Wang J, Huang G.

Drug Deliv. 2011 Nov;18(8):631-8. doi: 10.3109/10717544.2011.621988.

PMID:
22111976
11.

Preparation, characterization, and pharmacokinetics of sterically stabilized nimodipine-containing liposomes.

Yang D, Zhu J, Zheng Y, Ge L, Zhang G.

Drug Dev Ind Pharm. 2006 Feb;32(2):219-27. Erratum in: Drug Dev Ind Pharm. 2006 Jul;32(6):789.

PMID:
16537202
12.

Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis.

Ye J, Wang Q, Zhou X, Zhang N.

Int J Pharm. 2008 Mar 20;352(1-2):273-9. Epub 2007 Oct 22.

PMID:
18054182
13.

Modifying glycyrrhetinic acid liposomes with liver-targeting ligand of galactosylated derivative: preparation and evaluations.

Chen J, Chen Y, Cheng Y, Gao Y, Zheng P, Li C, Tong Y, Li Z, Luo W, Chen Z.

Oncotarget. 2017 Oct 27;8(60):102046-102066. doi: 10.18632/oncotarget.22143. eCollection 2017 Nov 24.

14.

Biodegradable self-assembled MPEG-PCL micelles for hydrophobic oridonin delivery in vitro.

Xue B, Wang Y, Tang X, Xie P, Wang Y, Luo F, Wu C, Qian Z.

J Biomed Nanotechnol. 2012 Feb;8(1):80-9.

PMID:
22515096
15.

The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats.

Dadashzadeh S, Vali AM, Rezaie M.

Int J Pharm. 2008 Apr 2;353(1-2):251-9. doi: 10.1016/j.ijpharm.2007.11.030. Epub 2007 Nov 23.

PMID:
18191511
16.

Development and pharmacokinetics of nimodipine-loaded liposomes.

Wang Z, Deng Y, Zhang X, Wang T, Wu F.

J Pharm Pharmacol. 2006 Sep;58(9):1289-94.

PMID:
16945189
17.

[Preparation of freeze-dried long-circulation oridonin liposomes and their pharmacokinetics in rats].

Lin H, Qu C, Yu Y, Tang Y, Sun X.

Zhejiang Da Xue Xue Bao Yi Xue Ban. 2013 Nov;42(6):638-43. Chinese.

PMID:
24421229
18.
19.

Oridonin nanosuspension enhances anti-tumor efficacy in SMMC-7721 cells and H22 tumor bearing mice.

Lou H, Gao L, Wei X, Zhang Z, Zheng D, Zhang D, Zhang X, Li Y, Zhang Q.

Colloids Surf B Biointerfaces. 2011 Oct 15;87(2):319-25. doi: 10.1016/j.colsurfb.2011.05.037. Epub 2011 May 27.

PMID:
21676599
20.

In vitro and in vivo antitumor activity of oridonin nanosuspension.

Lou H, Zhang X, Gao L, Feng F, Wang J, Wei X, Yu Z, Zhang D, Zhang Q.

Int J Pharm. 2009 Sep 8;379(1):181-6. doi: 10.1016/j.ijpharm.2009.06.022. Epub 2009 Jun 27.

PMID:
19563872

Supplemental Content

Support Center